New Global Guidelines Redefine Clinical Obesity Beyond BMI
Recent international guidelines, notably from The Lancet Diabetes & Endocrinology Commission, advocate for a new definition of 'clinical obesity' moving beyond Body Mass Index (BMI) alone. This shift aims for a more accurate diagnosis by considering fat distribution and its impact on organ health, rather than solely weight-to-height ratio.
Key Highlights
- BMI alone is insufficient for accurate obesity diagnosis.
- New global guidelines introduce 'clinical' and 'pre-clinical' obesity.
- Clinical obesity focuses on fat's impact on organ function.
- Waist circumference and other measures are crucial for diagnosis.
- The American Medical Association also acknowledges BMI limitations.
- Indian population has specific considerations for obesity diagnosis.
The traditional reliance on Body Mass Index (BMI) as the primary diagnostic tool for obesity is being challenged and redefined by global health experts. A recent article in The Indian Express, published on June 3, 2026, highlights this significant shift, explaining why BMI is no longer considered sufficient and introduces the new concept of 'clinical obesity' as defined by The Lancet Diabetes & Endocrinology Commission.
Numerous credible sources, including the American Medical Association (AMA) and the World Health Organization (WHO), corroborate the limitations of BMI. While BMI, calculated as weight in kilograms divided by the square of height in meters, has been a simple and inexpensive screening tool and useful for population-level surveillance, it presents several critical shortcomings at the individual level. It does not directly measure body fat, nor does it differentiate between fat mass and lean muscle mass, potentially misclassifying muscular individuals as obese. Furthermore, BMI fails to account for the distribution of body fat, particularly the more metabolically harmful visceral fat accumulated around organs in the abdomen, which is a stronger predictor of health risks than overall body fat percentage. It also doesn't inform practitioners about the origin or heterogeneity of obesity and its varied outcomes in specific individuals or populations. Crucially, BMI alone cannot reliably indicate the presence or severity of obesity-related health complications or organ dysfunction.
Recognizing these limitations, an international group of 58 leading experts from diverse medical specialties, forming The Lancet Diabetes & Endocrinology Commission, proposed a new consensus guideline for defining and diagnosing obesity in January 2025. This new framework moves beyond BMI as a standalone measure, aiming for a more precise and clinically actionable diagnosis. The core of this updated definition distinguishes between two categories: 'clinical obesity' and 'preclinical obesity'.
'Clinical obesity' is now defined as a chronic disease characterized by excess body fat that leads to active organ or tissue dysfunction, functional impairment, or significant limitations in daily life. This definition emphasizes the actual health consequences and impact of excess adiposity on a person's health, rather than just their size. It considers specific clinical markers such as diabetes, hypertension, non-alcoholic fatty liver disease with fibrosis, obstructive sleep apnea, and significant joint pain. The treatment for clinical obesity is thus geared towards improving or resolving these organ or tissue dysfunctions.
In contrast, 'preclinical obesity' refers to the presence of excess body fat that does not yet cause symptoms or physical impairment but places an individual at an increased risk for developing obesity-related diseases in the future. For these individuals, the focus of care is on risk reduction strategies.
The new guidelines recommend that for a diagnosis of obesity, especially when BMI is less than 40 kg/m2, additional anthropometric measures beyond BMI should be utilized. These include waist circumference, waist-to-hip ratio, and waist-to-height ratio. Direct measurements of subcutaneous and abdominal/intrahepatic fat mass, where available through technologies like CT, MRI, or DEXA, are also endorsed. The American Medical Association (AMA) also adopted a new policy in June 2023, urging medical professionals to conduct more comprehensive assessments for overweight and obesity, incorporating factors like visceral fat, body adiposity index, body composition, relative fat mass, waist circumference, and genetic/metabolic factors, rather than relying solely on BMI.
The Indian context is particularly relevant to this discussion. The Indian Express article notes that an associated publication proposed a specific definition for Indians, aligning with The Lancet's broader recommendations. This is crucial because individuals of Indian descent often exhibit higher body fat percentages and central obesity at lower BMI values compared to their Western counterparts, making them susceptible to obesity-related conditions like diabetes and cardiovascular diseases even within what might be considered a 'normal' BMI range for other ethnicities. Consequently, BMI cut-offs for overweight and obesity have been adjusted for Indians, with a BMI of 23-24.9 considered overweight and a BMI over 25 indicating obesity.
This paradigm shift underscores that obesity is a complex, chronic, and multifactorial disease, not merely a reflection of poor lifestyle choices or a high BMI. It involves interactions between genetic, environmental, behavioral, and metabolic factors. The move to a more comprehensive diagnostic approach is expected to better identify individuals who truly need treatment, personalize interventions, and ultimately improve health outcomes globally, including in India where the burden of obesity-related non-communicable diseases is substantial.
Frequently Asked Questions
Why is BMI no longer considered sufficient for diagnosing obesity?
BMI (Body Mass Index) has limitations because it doesn't directly measure body fat, nor does it account for fat distribution (like dangerous abdominal fat), muscle mass, or the actual health impact of excess fat on organs and bodily functions. It can misclassify individuals and miss those at high risk for obesity-related diseases.
What is 'clinical obesity' and how does it differ from traditional obesity definitions?
Clinical obesity, as defined by The Lancet Diabetes & Endocrinology Commission, is a chronic disease where excess body fat actively causes organ dysfunction, functional impairment, or significant limitations in daily life. Unlike traditional definitions that solely relied on BMI, it focuses on the health consequences and impact of adiposity, not just the weight-to-height ratio.
What are 'preclinical obesity' and 'clinical obesity'?
These are two categories introduced by new guidelines. 'Preclinical obesity' refers to having excess body fat without current symptoms or impairment, but with increased future health risks. 'Clinical obesity' signifies excess body fat that is already causing organ dysfunction, functional impairment, or significant health problems.
What additional measures are now recommended alongside BMI for obesity diagnosis?
Beyond BMI, experts now recommend incorporating other anthropometric measurements such as waist circumference, waist-to-hip ratio, and waist-to-height ratio. In some cases, direct measures of fat mass using advanced imaging techniques may also be used for a more comprehensive assessment.
How do these new definitions specifically impact the Indian population?
The new definitions are particularly relevant for India because individuals of Indian descent often have higher body fat percentages and central obesity at lower BMIs compared to Western populations, putting them at risk for diabetes and cardiovascular diseases at lower weight thresholds. This has led to adjusted, lower BMI cut-offs for overweight and obesity specifically for the Indian population.
